1-3
The G-BA (Federal Joint Committee) is charged with evaluating a medicine's additional benefit. 1, 4 Besides the extent of additional benefit versus an appropriate comparator, the quality of the evidence base, i.e. the evidence level, is evaluated in the EBA. 2, 4, 5 Pre-defined treatment switching, also called 'cross-over', is often seen in oncology clinical trials. Cross-over is usually implemented for ethical reasons, i.e. to ensure access to a beneficial-treatment for all patients, [6] [7] [8] but may confound data analysis, especially intention-to-treat (ITT)-analysis, by improving efficacy in the control arms. 7, [9] [10] [11] 
OBJECTIVES
Accounting for the ethical demand and the methodological issues, we investigated the impact of cross-over in clinical trials of oncology medicines evaluated by the EMA as well as by the G-BA in the German EBA process. Specifically, we determined whether the G-BA reflected the circumstances under which cross-over was implemented in its decision and if drugs with a cross-over were disadvantaged in their benefit assessment with regards to the evidence level. 
RESULTS

Figure 1: Analysis set
ONCOLOGY DRUGS WITHOUT CROSS-OVER STUDIES
CONCLUSIONS
• Oncology medicines with cross-over trials received better additional benefit ratings than those without. Evidence levels were worse, although crossover was ethically justified (i.e. implemented following demonstration of significant survival differences), indicating that the G-BA considers evidence standards to be only partially fulfilled in these cases.
• Highly efficacious drugs with ethically mandated cross-over are therefore disadvantaged with regard to the achievable evidence level.
• The requirements for an evidence level of proof should be reconsidered.
Medicines with a demonstration of superior efficacy in OS and cross-over recommended by a Data and Safety Monitoring Board (DSMB) deserve an evidence level of proof, irrelevant of the number of studies available for the assessment.
• In addition, the analysis of the hazard ratio for OS prior to cross-over should be acknowledged as final and meaningful data. * Oncology drugs granted no additional benefit were excluded from the evaluation of evidence levels (1 EBA in the group with and 2 EBAs in the group without cross-over). ** Number of EBAs with the best G-BA ratings granted in the analysis set (i.e. overall considerable additional benefit and evidence level of indication) were used to compare products with and without cross-over. CR/CRu, complete response and unconfirmed complete response; n.s. not significant; ORR, overall response rate; OS, overall survival; PAM, post-authorisation measure; PFS, progression-free survival; s., significant. * Hazard ratio evaluated. Significant differences between treatment arms defined as p < 0.05. Data represent first available data cut. † Overall score is stated. In case of different subgroups for a product, the best subgroup assessment is shown. In case of a re-assessment, the most recent assessment is shown. ‡ Data available before cross-over (for oncology drugs with cross-over studies in EBA). 
METHODS
Oncology medicines (excluding orphan drugs due to their automatically granted additional benefit) with EBAs finalised before 1 January 2015 were evaluated. Trials considered in the G-BA decisions were regarded as relevant for the analyses. Source documents included manufacturer's dossiers, G-BA decisions, European Public Assessment Reports and original trial publications. Presence of cross-over, analysis of clinical data (availability of, and evidence of significant differences in data on OS; data availability before cross-over for drugs with cross-over studies), EMA requests for additional data (i.e. conditional approval or post-authorisation measures [PAMs]), benefit ratings and evidence levels assigned by the G-BA were analysed. Cross-over was frequently used in oncology trials. For 11 of the 21 evaluated EBAs (52%), at least one trial assessed by the G-BA included cross-over (Figure 1 ). Significant differences in survival data between treatment groups were presented in 6 of the 11 trials (55%) with and in 6 of the 10 trials (60%) without cross-over. For all medicines with cross-over, significance was demonstrated prior to cross-over (Table 1) . The EMA most frequently required additional data if cross-over was performed, particularly if no survival data were available before cross-over (Table 1) . Medicines with cross-over received better additional benefit ratings than those without (73% vs 40%). The granted evidence levels showed an opposite trend (50% vs 75%). None of the medicines received an evidence level of proof (Table 1 and Figure 2 ). 
